富马酸奎的平与氯丙嗪治疗精神分裂症的对照研究

Comparison of efficacy and safety of qutipine and larctigal in the treament of schizophrenia

目的探讨富马酸奎的平治疗精神分裂症的临床疗效及安全性 ,并与盐酸氯丙嗪进行比较。方法 96例符合中国精神障碍分类与诊断标准 (CCMD 3 )的精神分裂症患者被随机分为两组 ,分别给予奎的平和氯丙嗪治疗 6周 ,以阳性和阴性症状量表 (PANSS)、临床总体印象量表 (CGI)进行疗效评定 ,以不良反应量表 (TESS)、实验室检查和生命体征进行副作用评定。结果共 88例完成试验 ,研究组 ( 4 6例 )总有效率为 60 .87% ,对照组 ( 4 2例 )为 61.90 % ,两组间差异均无显著性 ;研究组总的不良反应发生率为2 5 .0 0 % ,对照组为 66.67% ,差异有显著性 (P <0 .0 1)。结论富马酸奎的平治疗精神分裂症的疗效与氯丙嗪相当 ,不良反应发生率明显较低。

ObjectiveTo compare the efficacy and safety of qutipine and largactil in the treatment of schizophrenia. Methods96 schizophrenic patients were randomly treated with qutipine or lartigal for 6 weeks. The Positive and Negative Syndrom Scale (PANSS), CGI and Treatment Emergent Symptoms Scale (TESS) were used to evaluate efficacy and adverse effects before and after 2, 4 and 6 weeks treament. ResultsThe total efficacy rate of qutipine group and largactil group is 60.87% and 61.90% respectively after 6 weeks, without any significant difference between two groups (P>0.05). However, the incidence rate of adverse effect is 25.00% and 66.67% respectively, significantly lower in qutipine group (P<0.01). ConclusionsQutipine has a similar efficacy but fewer side effects compared with largactil.